Viela Bio: BLA for lead candidate, inebilizumab (anti-CD19 mAb), is under FDA review for the treatment of neuromyelitis optica spectrum disorder (NMOSD); PDUFA date June 11, 2020. VIB7734, anti-ILT7 mAb, Phase 1b interim data 1H20. Ph 2 trials ongoing for VIB4920 (Anti-CD40L-Tn3 Fusion Protein) in Sjogren's Syndrome and kidney transplant rejection. Additional trials with inebilizumab expected to initiate in 2020, including myasthenia gravis and IgG4-related disease.
Based in...
US - South Atlantic
Clinical Stage
Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune
Public, USA
Market Cap
1B +
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
United States

Top 10 Holders of Viela Bio, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 14.59 7,417,808 220.61 13F 6/30/20
Hillhouse Capital Advisors Ltd. 7.93 4,341,176 129.11 Stakes 10/3/19
Temasek Holdings Pte Ltd. 8.00 4,070,330 121.05 13F 6/30/20
Temasek Holdings Pte Ltd. (Investment Management) 7.44 4,070,330 121.05 Stakes 10/7/19
Hillhouse Capital Advisors Ltd. (Cayman Islands) 5.54 2,815,868 83.74 13F 6/30/20
Vanguard Group, Inc. (Subfiler) 3.96 2,013,337 59.88 13F 6/30/20
The Vanguard Group, Inc. 3.91 1,988,400 59.14 Funds 8/31/20
HBM Partners AG (Investment Management) 3.44 1,749,542 52.03 Funds 6/30/20
Cormorant Asset Management LP 2.97 1,512,500 44.98 13F 6/30/20
Viking Global Investors LP 2.06 1,049,000 31.20 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.